These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 21229645)
1. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression. Demir H; Turna H; Can G; Ilvan S J BUON; 2010; 15(4):774-82. PubMed ID: 21229645 [TBL] [Abstract][Full Text] [Related]
2. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas. Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150 [TBL] [Abstract][Full Text] [Related]
3. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray. Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951 [TBL] [Abstract][Full Text] [Related]
4. A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study. Chaiwun B; Nakrungsee S; Sukhamwang N; Srisukho S Breast Cancer; 2010; 17(1):35-41. PubMed ID: 19789946 [TBL] [Abstract][Full Text] [Related]
5. Ki-67 is a prognostic marker for hormone receptor positive tumors. Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937 [TBL] [Abstract][Full Text] [Related]
6. Triple-negative breast cancers: unique clinical presentations and outcomes. Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062 [TBL] [Abstract][Full Text] [Related]
7. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124 [TBL] [Abstract][Full Text] [Related]
8. Novel prognostic markers for patients with triple-negative breast cancer. Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466 [TBL] [Abstract][Full Text] [Related]
9. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification. Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304 [TBL] [Abstract][Full Text] [Related]
10. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions. Lew M; Pang JC; Jing X; Fields KL; Roh MH Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236 [TBL] [Abstract][Full Text] [Related]
11. [Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer]. Wang YJ; Wang N; Wang B; Qin WX; Xue CY Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):346-50. PubMed ID: 19799082 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. Intra M; Rotmensz N; Viale G; Mariani L; Bonanni B; Mastropasqua MG; Galimberti V; Gennari R; Veronesi P; Colleoni M; Tousimis E; Galli A; Goldhirsch A; Veronesi U Cancer; 2004 Sep; 101(5):905-12. PubMed ID: 15329896 [TBL] [Abstract][Full Text] [Related]
14. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization. Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E Oncology; 2012; 83(4):228-33. PubMed ID: 22907070 [TBL] [Abstract][Full Text] [Related]
15. Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer. Grönberg M; Fjällskog ML; Jirström K; Janson ET Acta Oncol; 2012 Mar; 51(3):386-93. PubMed ID: 22067021 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors. Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944 [TBL] [Abstract][Full Text] [Related]
17. Lack of prognostic significance of nm23 expression in human primary breast cancer. Göhring UJ; Eustermann I; Becker M; Neuhaus W; Rein DT; Schöndorf T Oncol Rep; 2002; 9(6):1205-8. PubMed ID: 12375020 [TBL] [Abstract][Full Text] [Related]
18. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. Park SS; Kim SW Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359 [TBL] [Abstract][Full Text] [Related]
19. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Steinman S; Wang J; Bourne P; Yang Q; Tang P Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367 [TBL] [Abstract][Full Text] [Related]
20. Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain. AlZaman AS; Mughal SA; AlZaman YS; AlZaman ES Saudi Med J; 2016 Jan; 37(1):37-42. PubMed ID: 26739972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]